Cytotechnology

, Volume 18, Issue 1, pp 93–106

Monitoring of immunotherapy with cytokines or monoclonal antibodies

  • C. Erik Hack
Article

DOI: 10.1007/BF00744324

Cite this article as:
Erik Hack, C. Cytotechnology (1995) 18: 93. doi:10.1007/BF00744324
  • 17 Downloads

Abstract

Recombinant cytokines and monoclonal antibodies (mAbs) are increasingly used in the treatment of a number of human diseases. Monitoring of the clinical efficacy of these agents requires specific clinical and laboratory measurements. A number of these novel therapies share common side effects, ranging from fever, headache and general malaise to hypotension, the development of edema leading to the vascular leak syndrome, the occurrence of thromboembolic processes and, in severe cases, organ dysfunction. As an example of the pathogenesis of these side effects, recent data are presented which were obtained in patients receiving immunotherapy with high doses of the cytokine interleukin-2 as an anti-cancer treatment.

Key words

Cytokines monoclonal antibody immunotherapy coagulation complement neutrophils hypotension vascular leak syndrome 

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • C. Erik Hack
    • 1
    • 2
  1. 1.Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Laboratory for Experimental and Clinical ImmunologyUniversity of AmsterdamAmsterdamThe Netherlands
  2. 2.Department of Internal MedicineFree University HospitalAmsterdamThe Netherlands

Personalised recommendations